冠状动脉微循环障碍治疗进展
Progress in the Treatment of Coronary Microvascular Dysfunction
DOI: 10.12677/ACM.2022.1281115, PDF,   
作者: 王 涵：重庆医科大学，重庆；苏 立*：重庆医科大学附属第二医院，重庆
关键词: 冠状动脉；微循环障碍；治疗；Coronary Artery； Microvascular Dysfunction； Treatment
摘要: 心绞痛或者心肌梗死传统上被认为是由阻塞性冠状动脉疾病引起的。然而，大量心绞痛患者或者一部分急性心肌梗死患者在接受冠状动脉造影或冠状动脉CT血管成像技术检查未见冠状动脉大血管狭窄或狭窄 < 50%，这些患者中有很大一部分患有冠状动脉微血管功能障碍(Coronary Microvascular Dysfunction, CMD)。CMD已被确定为心脏缺血的原因之一，冠状动脉微血管功能障碍可以单独发生，也可以与阻塞性冠状动脉疾病一起发生。随着侵入性和非侵入性技术的出现，在过去的几年中，冠状动脉微血管系统得到了更广泛的研究。不幸的是，尽管已确定CMD在几种情况下的病理生理学和预后作用，但迄今为止，还没有针对CMD的特异性治疗方法，我们主要讨论目前临床研究产生的潜在的治疗策略。
Abstract: Angina pectoris, or myocardial infarction, has traditionally been considered to be caused by ob-structive coronary artery disease. However, in a large number of patients with angina pectoris or some patients with acute myocardial infarction, coronary angiography or coronary CT angiography showed no coronary artery stenosis or stenosis. 50%, a large proportion of these patients have cor-onary microvascular dysfunction. Coronary microvascular dysfunction has been identified as one of the causes of cardiac ischemia. Coronary microvascular dysfunction may occur alone or in conjunc-tion with obstructive coronary artery disease. With the advent of non-invasive and invasive tech-nologies, the coronary microvascular system has been studied more extensively in the past few years. Unfortunately, although the pathophysiological and prognostic role of coronary microcircula-tion disorders has been established in several conditions. However, to date, there is no specific treatment for CMD, and we mainly discuss the potential treatment strategies arising from current clinical studies.
文章引用：王涵, 苏立. 冠状动脉微循环障碍治疗进展[J]. 临床医学进展, 2022, 12(8): 7734-7744. https://doi.org/10.12677/ACM.2022.1281115

参考文献

[1] Kostic, J., Djordjevic-Dikic, A., Dobric, M., Milasinovic, D., Nedeljkovic, M., Stojkovic, S., Stepanovic, J., Tesic, M., Trifunovic, Z., Zamaklar-Tifunovic, D., Radosavljevic-Radovanovic, M., Ostojic, M. and Beleslin, B. (2015) The Effects of Nicorandil on Microvascular Function in Patients with ST Segment Elevation Myocardial Infarction Undergoing Pri-mary PCI. Cardiovascular Ultrasound, 13, Article No 26. [Google Scholar] [CrossRef] [PubMed]
[2] Hirohata, A., Yamamoto, K., Hirose, E., Kobayashi, Y., Takafuji, H., Sano, F., Matsumoto, K., Ohara, M., Yoshioka, R., Takinami, H. and Ohe, T. (2014) Nicorandil Prevents Microvas-cular Dysfunction Resulting from PCI in Patients with Stable Angina Pectoris: A Randomised Study. EuroIntervention, 9, 1050-1056. [Google Scholar] [CrossRef] 
[3] Shimokawa, H., Sunamura, S. and Satoh, K. (2016) RhoA/Rho-Kinase in the Cardiovascular System. Circulation Research, 118, 352-366. [Google Scholar] [CrossRef] 
[4] Masumoto, A., Mohri, M., Shimokawa, H., Urakami, L., Usui, M. and Takeshita, A. (2002) Suppression of Coronary Artery Spasm by the Rho-Kinase Inhibitor Fasudil in Pa-tients with Vasospastic Angina. Circulation, 105, 1545-1547. [Google Scholar] [CrossRef] [PubMed]
[5] Suda, A., Takahashi, J., Hao, K., Kikuchi, Y., Shindo, T., Ikeda, S., Sato, K., Sugisawa, J., Matsumoto, Y., Miyata, S., Sakata, Y. and Shimokawa, H. (2019) Coronary Functional Abnor-malities in Patients with Angina and Nonobstructive Coronary Artery Disease. Journal of the American College of Car-diology, 74, 2350-2360. [Google Scholar] [CrossRef] [PubMed]
[6] Satoh, K., Fukumoto, Y. and Shimokawa, H. (2011) Rho-Kinase: Important New Therapeutic Target in Cardiovascular Diseases. American Journal of Physiology - Heart and Circulatory Physiology, 301, H287-H296. [Google Scholar] [CrossRef] [PubMed]
[7] Nihei, T., Takahashi, J., Hao, K., Kikuchi, Y., Odaka, Y., Tsuburaya, R., Nishimiya, K., Matsumoto, Y., Ito, K., Miyata, S., Sakata, Y. and Shimokawa, H. (2018) Prognostic Im-pacts of Rho-Kinase Activity in Circulating Leucocytes in Patients with Vasospastic Angina. European Heart Journal, 39, 952-959. [Google Scholar] [CrossRef] [PubMed]
[8] Neglia, D., Fommei, E., Varela-Carver, A., Mancini, M., Ghione, S., Lombardi, M., Pisani, P., Parker, H., D’Amati, G., Donato, L. and Camici, P.G. (2011) Perindopril and In-dapamide Reverse Coronary Microvascular Remodelling and Improve Flow in Arterial Hypertension. Journal of Hyper-tension, 29, 364-372. [Google Scholar] [CrossRef] 
[9] Pauly, D.F., Johnson, B.D., Anderson, R.D., Handberg, E.M., Smith, K.M., Cooper-DeHoff, R.M., Sopko, G., Sharaf, B.M., Kelsey, S.F., Merz, C.N. and Pepine, C.J. (2011) In Women with Symptoms of Cardiac Ischemia, Nonobstructive Coronary Arteries, and Microvascular Dysfunction, Angiotensin-Converting Enzyme Inhibition Is Associated with Improved Microvascular Function: A Double-Blind Ran-domized Study from the National Heart, Lung and Blood Institute Women’s Ischemia Syndrome Evaluation (WISE). American Heart Journal, 162, 678-684. [Google Scholar] [CrossRef] [PubMed]
[10] Masuda, D., Nohara, R., Tamaki, N., Hosokawa, R., Inada, H., Hikai, T., Chen, L.G., Tadamura, E., Kudou, T., Konishi, J., Fujita, M. and Sasayama, S. (2000) Evaluation of Coronary Blood Flow Reserve by 13N-NH3 Positron Emission Computed Tomography (PET) with Dipyridamole in the Treatment of Hypertension with the ACE Inhibitor (Cilazapril). Annals of Nuclear Medicine, 14, 353-360. [Google Scholar] [CrossRef] 
[11] Higuchi, T., Abletshauser, C., Nekolla, S.G., Schwaiger, M. and Bengel, F.M. (2007) Effect of the Angiotensin Receptor Blocker Valsartan on Coronary Microvascular Flow Reserve in Moder-ately Hypertensive Patients with Stable Coronary Artery Disease. Microcirculation, 14, 805-812. [Google Scholar] [CrossRef] [PubMed]
[12] Kawata, T., Daimon, M., Hasegawa, R., Teramoto, K., Toyoda, T., Sekine, T., Yamamoto, K., Uchida, D., Himi, T., Yoshida, K. and Komuro, I. (2006) Effect on Coronary Flow Veloc-ity Reserve in Patients with Type 2 Diabetes Mellitus: Comparison between Angiotensin-Converting Enzyme Inhibitor and Angiotensin II Type 1 Receptor Antagonist. American Heart Journal, 151, 798.e9-798.e15. [Google Scholar] [CrossRef] [PubMed]
[13] Akinboboye, O.O., Chou, R.L. and Bergmann, S.R. (2002) Aug-mentation of Myocardial Blood Flow in Hypertensive Heart Disease by Angiotensin Antagonists: A Comparison of Lis-inopril and Losartan. Journal of the American College of Cardiology, 40, 703-709. [Google Scholar] [CrossRef] 
[14] Sütsch, G., Oechslin, E., Mayer, I. and Hess, O.M. (1995) Effect of Diltiazem on Coronary Flow Reserve in Patients with Microvascular Angina. International Journal of Cardiol-ogy, 52, 135-143. [Google Scholar] [CrossRef] [PubMed]
[15] Nishigaki, K., Inoue, Y., Yamanouchi, Y., Fukumoto, Y., Yasuda, S., Sueda, S., Urata, H., Shimokawa, H. and Minatoguchi, S. (2010) Prognostic Effects of Calcium Channel Blockers in Patients with Vasospastic Angina—A Meta-Analysis. Circulation Journal, 74, 1943-1950. [Google Scholar] [CrossRef] 
[16] Fukumoto, Y., Yasuda, S., Ito, A. and Shimokawa, H. (2008) Prog-nostic Effects of Benidipine in Patients with Vasospastic Angina: Comparison with Diltiazem and Amlodipine. Journal of Cardiovascular Pharmacology, 51, 253-257. [Google Scholar] [CrossRef] 
[17] Mehta, P.K., Goykhman, P., Thomson, L.E., Shufelt, C., Wei, J., Yang, Y., Gill, E., Minissian, M., Shaw, L.J., Slomka, P.J., Slivka, M., Berman, D.S. and Bairey, M.C.N. (2011) Ranolazine Improves Angina in Women with Evidence of Myocardial Ischemia but No Obstructive Coronary Artery Disease. JACC: Cardiovascular Imagingg, 4, 514-522. [Google Scholar] [CrossRef] [PubMed]
[18] Rambarat, C.A., Elgendy, I.Y., Handberg, E.M., Bairey, M.C.N., Wei, J., Minissian, M.B., Nelson, M.D., Thomson, L.E.J., Berman, D.S., Shaw, L.J., Cook-Wiens, G. and Pepine, C.J. (2019) Late Sodium Channel Blockade Improves Angina and Myocardial Perfusion in Patients with Severe Coronary Microvascular Dysfunction: Women’s Ischemia Syndrome Evaluation-Coronary Vascular Dysfunction Ancillary Study. International Journal of Cardiology, 276, 8-13. [Google Scholar] [CrossRef] [PubMed]
[19] Bairey, M.C.N., Handberg, E.M., Shufelt, C.L., Mehta, P.K., Minissian, M.B., Wei, J., Thomson, L.E., Berman, D.S., Shaw, L.J., Petersen, J.W., Brown, G.H., Anderson, R.D., Shuster, J.J., Cook-Wiens, G., Rogatko, A. and Pepine, C.J. (2016) A Randomized, Placebo-Controlled Trial of Late Na Current Inhibition (Ranolazine) in Coronary Microvascular Dysfunction (CMD): Impact on Angina and Myocardial Per-fusion Reserve. European Heart Journal, 37, 1504-1513. [Google Scholar] [CrossRef] [PubMed]
[20] Shah, N.R., Cheezum, M.K., Veeranna, V., Horgan, S.J., Taqueti, V.R., Murthy, V.L., Foster, C., Hainer, J., Daniels, K.M., Rivero, J., Shah, A.M., Stone, P.H., Morrow, D.A., Steigner, M.L., Dorbala, S., Blankstein, R. and Di Carl, M.F.I. (2017) Ranolazine in Symptomatic Diabetic Patients without Ob-structive Coronary Artery Disease: Impact on Microvascular and Diastolic Function. Journal of the American Heart As-sociation, 6, Article ID: e005027. [Google Scholar] [CrossRef] 
[21] Koh, J.S., Hung, O.Y., Eshtehardi, P., Kumar, A., Rabah, R., Raad, M., Kumar, S., Chaudhry, S., Gupta, S., Hosseini, H., Brilakis, E., Corban, M., Sabbak, N., Burnett, G.M., Liu, C., Me-hta, P.K., Quyyumi, A.A. and Samady, H. (2020) Microvascular Assessment of Ranolazine in Non-Obstructive Athero-sclerosis: The MARINA Randomized, Double- Blinded, Controlled Pilot Trial. Circulation: Cardiovascular Interven-tions, 13, Article ID: e008204. [Google Scholar] [CrossRef] 
[22] Rogacka, D., Guzik, P., Wykretowicz, A., Rzeźniczak, J., Dziarmaga, M. and Wysocki, H. (2000) Effects of Trimetazidine on Clinical Symptoms and Tolerance of Exercise of Patients with Syndrome X: A Preliminary Study. Coronary Artery Disease, 11, 171-177. [Google Scholar] [CrossRef] [PubMed]
[23] Chiang, C.Y., Chien, C.Y., Qiou, W.Y., Chang, C., Yu, I.S., Chang, P.Y. and Chien, C.T. (2018) Genetic Depletion of Thromboxane A2/Thromboxane-Prostanoid Receptor Signalling Prevents Microvascular Dysfunction in Ischaemia/ Reperfusion Injury. Thrombosis and Haemostasis, 118, 1982-1996. [Google Scholar] [CrossRef] [PubMed]
[24] Park, K., Cho, Y.R., Park, J.S., Park, T.H., Kim, M.H. and Kim, Y.D. (2019) Comparison of the Effects of Ticagrelor and Clopidogrel on Microvascular Dysfunction in Patients with Acute Coronary Syndrome Using Invasive Physiologic Indices. Circulation: Cardiovascular Interventions, 12, Ar-ticle ID: e008105. [Google Scholar] [CrossRef] 
[25] Scanavini-Filho, M.A., Berwanger, O., Mat-thias, W., Aguiar, M.O., Chiang, H.P., Azevedo, L., Baracioli, L.M., Lima, F.G., Furtado, R.H.M., Dalcoquio, T.F., Menezes, F.R., Ferrari, A.G., De Luca, F., Giugliano, R.P., Goodman, S. and Nicolau, J.C. (2022) Effects of Ticagrelor and Clopidogrel on Coronary Microcirculation in Patients with Acute Myocardial Infarction. Advances in Therapy, 39, 1832-1843. [Google Scholar] [CrossRef] [PubMed]
[26] Kayikcioglu, M., Payzin, S., Yavuzgil, O., Kultursay, H., Can, L.H. and Soydan, I. (2003) Benefits of Statin Treatment in Cardiac Syndrome-X1. European Heart Journal, 24, 1999-2005. [Google Scholar] [CrossRef] 
[27] Caliskan, M., Erdogan, D., Gullu, H., Topcu, S., Ciftci, O., Yildirir, A. and Muderrisoglu, H. (2007) Effects of Atorvastatin on Coronary Flow Reserve in Patients with Slow Coronary Flow. Clinical Cardiology, 30, 475-479. [Google Scholar] [CrossRef] [PubMed]
[28] Quyyumi, A.A., Dakak, N., Andrews, N.P., Gilligan, D.M., Panza, J.A. and Cannon III, R.O. (1995) Contribution of Nitric Oxide to Metabolic Coronary Vasodilation in the Human Heart. Circula-tion, 92, 320-326. [Google Scholar] [CrossRef] 
[29] Togni, M., Vigorito, F., Windecker, S., Abrecht, L., Wenaweser, P., Cook, S., Billinger, M., Meier, B. and Hess, O.M. (2007) Does the Beta-Blocker Nebivolol Increase Coronary Flow Reserve? Cardiovascular Drugs and Therapy, 21, 99-108. [Google Scholar] [CrossRef] [PubMed]
[30] Galderisi, M. and D’Errico, A. (2008) Beta-Blockers and Coro-nary Flow Reserve: The Importance of a Vasodilatory Action. Drugs, 68, 579-590. [Google Scholar] [CrossRef] [PubMed]
[31] Borer, J.S., Fox, K., Jaillon, P. and Lerebours, G. (2003) Antianginal and Antiischemic Effects of Ivabradine, an I(f) Inhibitor, in Stable Angina: A Randomized, Double-Blind, Multicentered, Placebo-Controlled Trial. Circulation, 107, 817-823. [Google Scholar] [CrossRef] 
[32] Skalidis, E.I., Hamilos, M.I., Chlouverakis, G., Zacha-ris, E.A. and Vardas, P.E. (2011) Ivabradine Improves Coronary Flow Reserve in Patients with Stable Coronary Artery Disease. Atherosclerosis, 215, 160-165. [Google Scholar] [CrossRef] [PubMed]
[33] Egashira, K., Hirooka, Y., Kuga, T., Mohri, M. and Takeshita, A. (1996) Effects of L-Arginine Supplementation on Endothelium-Dependent Coronary Vasodilation in Pa-tients with Angina Pectoris and Normal Coronary Arteriograms. Circulation, 94, 130-134. [Google Scholar] [CrossRef] 
[34] Lerman, A., Burnett Jr., J.C., Higano, S.T., McKinley, L.J. and Holmes Jr., D.R. (1998) Long-Term L-Arginine Supplementation Improves Small-Vessel Coronary Endothelial Function in Humans. Circulation, 97, 2123-2128. [Google Scholar] [CrossRef] 
[35] Najjar, R.S., Schwartz, A.M., Wong, B.J., Mehta, P.K. and Feresin, R.G. (2021) Berries and Their Polyphenols as a Potential Therapy for Coronary Microvascular Dysfunction: A Mini-Review. International Journal of Molecular Sciences, 22, Article No. 3373. [Google Scholar] [CrossRef] [PubMed]
[36] Xuan, C., Tian, Q.W., Li, H., Zhang, B.B., He, G.W. and Lun, L.M. (2016) Levels of Asymmetric Dimethylarginine (ADMA), an Endogenous Nitric Oxide Synthase Inhibitor, and Risk of Coronary Artery Disease: A Meta-Analysis Based on 4713 Participants. European Journal of Preventive Cardiolog, 23, 502-510. [Google Scholar] [CrossRef] [PubMed]
[37] Suda, O., Tsutsui, M., Morishita, T., Tasaki, H., Ueno, S., Nakata, S., Tsujimoto, T., Toyohira, Y., Hayashida, Y., Sasaguri, Y., Ueta, Y., Nakashima, Y. and Yanagihara, N. (2004) Asymmetric Dimethylarginine Produces Vascular Lesions in Endothelial Nitric Oxide Synthase-Deficient Mice: In-volvement of Renin-Angiotensin System and Oxidative Stress. Arteriosclerosis, Thrombosis, and Vascular Biology, 24, 1682-1688. [Google Scholar] [CrossRef] 
[38] Verhaar, M.C., Strachan, F.E., Newby, D.E., Cruden, N.L., Koomans, H.A., Rabelink, T.J. and Webb, D.J. (1998) Endothelin-A Receptor Antagonist-Mediated Vasodilatation Is Attenuated by Inhibition of Nitric Oxide Synthesis and by Endothelin-B Receptor Blockade. Circulation, 97, 752-756. [Google Scholar] [CrossRef] 
[39] Ford, T.J., Rocchiccioli, P., Good, R., McEntegart, M., Eteiba, H., Watkins, S., Shaukat, A., Lindsay, M., Robertson, K., Hood, S., Yii, E., Sidik, N., Harvey, A., Montezano, A.C., Beattie, E., Haddow, L., Oldroyd, K.G., Touyz, R.M. and Berry, C. (2018) Systemic Microvascular Dysfunction in Microvascu-lar and Vasospastic Angina. European Heart Journal, 39, 4086-4097. [Google Scholar] [CrossRef] [PubMed]
[40] Naya, M., Aikawa, T., Manabe, O., Obara, M., Koyanagawa, K., Katoh, C. and Tamaki, N. (2021) Elevated Serum Endothelin-1 Is an Independent Predictor of Coronary Microvascular Dysfunction in Non-Obstructive Territories in Patients with Coronary Artery Disease. Heart and Vessels, 36, 917-923. [Google Scholar] [CrossRef] [PubMed]
[41] Kaski, J.C., Elliott, P.M., Salomone, O., Dickinson, K., Gordon, D., Hann, C. and Holt, D.W. (1995) Concentration of Circulating Plasma Endothelin in Patients with Angina and Normal Coronary Angiograms. Heart, 74, 620-624. [Google Scholar] [CrossRef] [PubMed]
[42] Yoon, M.H., Reriani, M., Mario, G., Rihal, C., Gulati, R., Lennon, R., Tilford, J.M., Lerman, L.O. and Lerman, A. (2013) Long-Term Endothelin Receptor Antagonism Attenuates Coronary Plaque Progression in Patients with Early Atherosclerosis. International Journal of Cardiology, 168, 1316-1321. [Google Scholar] [CrossRef] [PubMed]
[43] Reriani, M., Raichlin, E., Prasad, A., Mathew, V., Pumper, G.M., Nelson, R.E., Lennon, R., Rihal, C., Lerman, L.O. and Lerman, A. (2010) Long-Term Administration of Endothelin Re-ceptor Antagonist Improves Coronary Endothelial Function in Patients with Early Atherosclerosis. Circulation, 122, 958-966. [Google Scholar] [CrossRef] 
[44] Halcox, J.P., Nour, K.R., Zalos, G. and Quyyumi, A.A. (2001) Coronary Vasodilation and Improvement in Endothelial Dysfunction with Endothelin ET(A) Receptor Blockade. Circulation Research, 89, 969-976. [Google Scholar] [CrossRef] [PubMed]
[45] Tawakol, A., Forgione, M.A., Stuehlinger, M., Alpert, N.M., Cooke, J.P., Loscalzo, J., Fischman, A.J., Creager, M.A. and Gewirtz, H. (2002) Homocysteine Impairs Coronary Microvascu-lar Dilator Function in Humans. Journal of the American College of Cardiology, 40, 1051-1058. [Google Scholar] [CrossRef] 
[46] Bleie, Ø., Strand, E., Ueland, P.M., Vollset, S.E., Refsum, H., Igland, J., Nordrehaug, J.E. and Nygård, O.K. (2011) Coronary Blood Flow in Patients with Stable Coronary Artery Disease Treated Long Term with Folic Acid and Vitamin B12. Coronary Artery Disease, 22, 270-278. [Google Scholar] [CrossRef] 
[47] Tawakol, A., Migrino, R.Q., Aziz, K.S., Waitkowska, J., Holmvang, G., Alpert, N.M., Muller, J.E., Fischman, A.J. and Gewirtz, H. (2005) High-Dose Folic Acid Acutely Im-proves Coronary Vasodilator Function in Patients with Coronary Artery Disease. Journal of the American College of Cardiology, 45, 1580-1584. [Google Scholar] [CrossRef] [PubMed]
[48] Watanabe, K., Ikeda, S., Komatsu, J., Inaba, S., Suzuki, J., Sueda, S., Funada, J., Kitakaze, M. and Sekiya, M. (2003) Effect of Cilostazol on Vasomotor Reactivity in Patients with Vaso-spastic Angina Pectoris. American Journal of Cardiology, 92, 21-25. [Google Scholar] [CrossRef] 
[49] Shin, E.S., Lee, J.H., Yoo, S.Y., Park, Y., Hong, Y.J., Kim, M.H., Lee, J.Y., Nam, C.W., Tahk, S.J., Kim, J.S., Jeong, Y.H., Lee, C.W., Shin, H.K. and Kim, J.H. (2014) A Ran-domised, Multicentre, Double Blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Cilostazol in Patients with Vasospastic Angina. Heart, 100, 1531-1536. [Google Scholar] [CrossRef] [PubMed]
[50] Halcox, J.P., Nour, K.R., Zalos, G., Mincemoyer, R.A., Waclawiw, M., Rivera, C.E., Willie, G., Ellahham, S. and Quyyumi, A.A. (2002) The Effect of Sildenafil on Human Vascular Function, Platelet Activation, and Myocardial Ischemia. Journal of the American College of Cardiology, 40, 1232-1240. [Google Scholar] [CrossRef] 
[51] Traverse, J.H., Chen, Y.J., Du, R. and Bache, R.J. (2000) Cyclic Nucleotide Phosphodiesterase Type 5 Activity Limits Blood Flow to Hypoperfused Myocardium During Exercise. Circulation, 102, 2997-3002. [Google Scholar] [CrossRef] 
[52] Robinson, S.D., Ludlam, C.A., Boon, N.A. and Newby, D.E. (2006) Phosphodiesterase Type 5 Inhibition Does Not Reverse Endothelial Dysfunction in Patients with Coronary Heart Disease. Heart, 92, 170-176. [Google Scholar] [CrossRef] [PubMed]
[53] Henry, T.D., Bairey, M.C.N., Wei, J., Corban, M.T., Quesada, O., Joung, S., Kotynski, C.L., Wang, J., Lewis, M., Schumacher, A.M., Bartel, R.L., Takagi, H., Shah, V., Lee, A., Sietsema, W.K., Losordo, D.W. and Lerman, A. (2022) Autologous CD34+ Stem Cell Therapy Increases Coronary Flow Reserve and Reduces Angina in Patients with Coronary Microvascular Dysfunction. Circulation: Cardiovascular Interventions, 15, Article ID: e010802. [Google Scholar] [CrossRef] 
[54] Corban, M.T., Toya, T., Albers, D., Sebaali, F., Lewis, B.R., Bois, J., Gulati, R., Prasad, A., Best, P.J.M., Bell, M.R., Rihal, C.S., Prasad, M., Ahmad, A., Lerman, L.O., Solseth, M.L., Winters, J.L., Dietz, A.B. and Lerman, A. (2022) IMPROvE-CED Trial: Intracoronary Autologous CD34+ Cell Therapy for Treatment of Coronary Endothelial Dysfunction in Patients with Angina and Nonobstructive Coronary Arteries. Circulation Research, 130, 326-338. [Google Scholar] [CrossRef] 
[55] Jadhav, S., Ferrell, W., Greer, I.A., Petrie, J.R., Cobbe, S.M. and Sattar, N. (2006) Effects of Metformin on Microvascular Function and Exercise Tolerance in Women with An-gina and Normal Coronary Arteries: A Randomized, Double-Blind, Placebo-Controlled Study. Journal of the American College of Cardiology, 48, 956-963. [Google Scholar] [CrossRef] [PubMed]
[56] Merz, C.N., Olson, M.B., McClure, C., Yang, Y.C., Symons, J., Sopko, G., Kelsey, S.F., Handberg, E., Johnson, B.D., Cooper-DeHoff, R.M., Sharaf, B., Rogers, W.J. and Pepine, C.J. (2010) A Randomized Controlled Trial of Low-Dose Hormone Therapy on Myocardial Ischemia in Postmenopausal Women with No Obstructive Coronary Artery Disease: Results from the National Institutes of Health/National Heart, Lung, and Blood Institute-Sponsored Women’s Ischemia Syndrome Evaluation (WISE). American Heart Journal, 159, 987.e1-987.e7. [Google Scholar] [CrossRef] [PubMed]
[57] Pedersen, L.R., Olsen, R.H., Anholm, C., Astrup, A., Eugen-Olsen, J., Fenger, M., Simonsen, L., Walzem, R.L., Haugaard, S.B. and Prescott, E. (2019) Effects of 1 Year of Exercise Training Versus Combined Exercise Training and Weight Loss on Body Composition, Low-Grade Inflamma-tion and Lipids in Overweight Patients with Coronary Artery Disease: A Randomized Trial. Cardiovascular Diabetology, 18, Article No. 127. [Google Scholar] [CrossRef] [PubMed]
[58] Olsen, R.H., Pedersen, L.R., Jürs, A., Snoer, M., Haugaard, S.B. and Prescott, E. (2015) A Randomised Trial Comparing the Effect of Exercise Training and Weight Loss on Microvascu-lar Function in Coronary Artery Disease. International Journal of Cardiology, 185, 229-235. [Google Scholar] [CrossRef] [PubMed]
[59] Eriksson, B.E., Tyni-Lennè, R., Svedenhag, J., Hallin, R., Jen-sen-Urstad, K., Jensen-Urstad, M., Bergman, K. and Selvén, C. (2000) Physical Training in Syndrome X: Physical Training Counteracts Deconditioning and Pain in Syndrome X. ournal of the American College of Cardiology, 36, 1619-1625. [Google Scholar] [CrossRef] 
[60] Tyni-Lenne, R., Stryjan, S., Eriksson, B., Berglund, M. and Sylven, C. (2002) Beneficial Therapeutic Effects of Physical Training and Relaxation Therapy in Women with Coronary Syndrome X. Physiotherapy Research International, 7, 35-43. [Google Scholar] [CrossRef] [PubMed]
[61] Sgueglia, G.A., Sestito, A., Spinelli, A., Cioni, B., Infusino, F., Papacci, F., Bellocci, F., Meglio, M., Crea, F. and Lanza, G.A. (2007) Long-Term Follow-Up of Patients with Cardiac Syndrome X Treated by Spinal Cord Stimulation. Heart, 93, 591-597. [Google Scholar] [CrossRef] [PubMed]
[62] Lanza, G.A., Sestito, A., Sgueglia, G.A., Infusino, F., Papacci, F., Visocchi, M., Ierardi, C., Meglio, M., Bellocci, F. and Crea, F. (2005) Effect of Spinal Cord Stimulation on Spontaneous and Stress-Induced Angina and ‘Ischemia-Like’ ST-Segment Depression in Patients with Cardiac Syndrome X. Europe-an Heart Journal, 26, 983-989. [Google Scholar] [CrossRef] [PubMed]
[63] Kronhaus, K.D. and Lawson, W.E. (2009) Enhanced External Coun-terpulsation Is an Effective Treatment for Syndrome X. International Journal of Cardiology, 135, 256-257. [Google Scholar] [CrossRef] [PubMed]
[64] Loh, P.H., Louis, A.A., Windram, J., Rigby, A.S., Cook, J., Hur-ren, S., Nikolay, N.P., Caplin, J. and Cleland, J.G. (2006) The Immediate and Long-Term Outcome of Enhanced External Counterpulsation in Treatment of Chronic Stable Refractory Angina. Journal of Internal Medicine, 259, 276-284. [Google Scholar] [CrossRef] [PubMed]

为你推荐